Study: Psych drug ads misleading

Ads for psych drugs in medical journals are often misleading, a new study shows. Half the claims made in these ads offered no backup source that could be verified--and of those that were backed up by verifiable citations, almost half the cited studies didn't even support the claims. In some cases, the cited studies directly contradicted the ad's contentions. "When claims are made that aren't supported, the impression created is overly optimistic," lead author Glen Spielmans said.

Curiouser and curiouser, when the researchers asked nine drugmakers about the ads, only three replied, one of them to refuse to supply the sources of data it cited in its own advertising. That company? Wyeth. Ironically, the Effexor XR ad in question is actually headlined "See the data." Now you see it, now you don't.

- check out the study in the Journal of Nervous and Mental Disease
- see the item in Pharmalot

Related Articles:
Studies inflating antidepressant efficacy? Report
To DTC or not to DTC? Report
Does the FDA do enough to regulate drug ads? FDA report
10 reforms for drug advertising. Drug ad report

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.